Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 23, 2021updated 07 Jan 2022 7:25am

Mereo, UAB report positive data from Phase Ib/II Covid-19 oral drug trial 

In the trial, 62.5% in the alvelestat group had a two-point decline in the WHO Disease Severity score by day five.

Mereo BioPharma and the University of Alabama at Birmingham (UAB) in the US have reported positive results from the Phase Ib/II COSTA clinical trial of a new oral drug, alvelestat, in hospitalised Covid-19 patients with respiratory disease.

Alvelestat is an active inhibitor of Neutrophil Elastase (NE).

The randomised, placebo-controlled, single-site, double-blind, investigator-led trial assessed the safety and tolerability of alvelestat plus standard of care (SOC) in adult subjects aged 18 years and above with Covid-19 respiratory disease.

Subjects were given alvelestat or placebo twice a day for five days with an option to extend the treatment to ten days as per the investigator’s choice.

The primary goal was safety and tolerability to day 60, with mortality analysis at day 90.

Clinical outcomes to day 60 were the trial’s secondary goals.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Findings showed that alvelestat was safe and well-tolerated in Covid-19-infected individuals.

No safety signals were reported in lab safety monitoring which is in line with the already reported safety profile of the oral drug.

In the trial, four subjects who received alvelestat had treatment-emergent headaches which were more frequent than placebo arm with one case observed.

This event was concluded to be not linked to the trial drug with no difference in frequency of other adverse events between alvelestat and placebo groups noted till day 60.

Alvelestat plus SOC offered a quicker time to improvement in WHO Disease Severity score of >=2 in the initial five to seven days versus placebo plus SOC.

By day five, nearly 62.5% of the subjects in the alvelestat arm exhibited a two-point decline in the WHO Disease Severity score versus 28.5% in the placebo group.

Furthermore, on day seven, the alvelestat arm’s improvement score climbed to 87.5% as against 57% in subjects who received placebo.

UAB Pulmonary, Allergy and Critical Care Medicine associate professor Dr Mike Wells said: “The early results with alvelestat suggest a potential for clinical benefit over and above the standard of care including dexamethasone and remdesivir.

“This is exciting given the ease of administration of a well-tolerated oral therapy in this acutely ill population. These findings provide strong data and set the stage for future studies with relevant clinical end-points.”

In December 2018, Mereo BioPharma announced plans to merge business with OncoMed Pharmaceuticals.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU